Treatment of Severe Aortic Stenosis with Transfemoral TAVI with or Without Coronary Angiogram During Diagnostic Work-up (PURE TAVI)
Launched by REDE OPTIMUS HOSPITALAR SA · Mar 20, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study aims to evaluate whether a TAVI pathway without prior coronary angiography is non-inferior to a conventional TAVI pathway, in which routine coronary angiography with or without revascularization is included, in patients with significant aortic stenosis who do not experience typical angina pectoris classified as CCS 3 or higher.
Hypothesis: For patients with significant aortic stenosis who do not experience typical angina pectoris classified as CCS 3 or higher, omitting a coronary angiography prior to or during transfemoral TAVI is non-inferior to a traditional diagnostic work-up...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is older than 18 years with severe AS considered for TAVI by a multidisciplinary heart team.
- • Patient is candidate for transfemoral TAVI as per local standards and current guidelines.
- • Patient is willing and capable to give written consent to participate to the trial and confirmed to be able to attend the expected follow up visits.
- Exclusion Criteria:
- • Patient had a coronary angiogram with or without PCI and/or coronary CT and/or CABG within last 5 years.
- • Left main PCI in the medical history
- • Patient has CCS of 3 or more.
- • Patient has left ventricular ejection fraction \<30%.
- • Patients in whom TAVI through femoral access is ad priori not possible based on clinical assessment or medical history
- • Patient has been treated for acute myocardial infarction within 30 days before randomization.
- • Patient has a planned open-heart surgery.
- • Patient has a life expectancy less than 1 year due to other severe non-cardiac disease.
- • Patient is participating in another clinical study with an investigational product that has not yet completed the follow up period.
- • Patient has received previous treatment for aortic valve implantation or replacement.
- • Female patient who is pregnant at the time of inclusion.
Trial Officials
Dr. William Wijns, Professor
Study Chair
Dr. Gabor G Toth, Professor
Study Chair
Dr. Felix Mahfoud, Professor
Study Chair
Flavio Ribichini, Professor
Study Chair
Dr. Emanuele Barbato, Professor
Study Chair
Dr. Peter Jüni, Professor
Study Chair
About Rede Optimus Hospitalar Sa
Rede Optimus Hospitalar SA is a leading healthcare organization committed to advancing medical research and improving patient outcomes through innovative clinical trials. With a focus on excellence in patient care and a robust infrastructure, the organization collaborates with healthcare professionals and research institutions to facilitate the development of cutting-edge therapies. By prioritizing ethical standards and regulatory compliance, Rede Optimus Hospitalar SA aims to contribute significantly to the medical community and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported